Home/Pipeline/InflammaD

InflammaD

Back-of-the-eye inflammation (e.g., DME, RVO, uveitis)

FeasibilityActive

Key Facts

Indication
Back-of-the-eye inflammation (e.g., DME, RVO, uveitis)
Phase
Feasibility
Status
Active
Company

About EyeD Pharma

EyeD Pharma is a private, clinical-stage biotech based in Liège, Belgium, focusing on novel drug delivery for ophthalmology. Its core technology platform involves sustained-release polymeric micro-implants designed to enhance patient compliance and reduce side effects associated with traditional eye drop regimens. The pipeline includes programs for glaucoma (TimoD in Phase I), dry eye disease (HydraD in pre-clinical), and back-of-the-eye inflammation (InflammaD in feasibility), targeting large, growing patient populations. With over 100 employees and an internal CDMO, the company pursues a fully integrated development and manufacturing strategy.

View full company profile